Back to Search Start Over

Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissue.

Authors :
Sen M
Hahn F
Black TA
DeMarshall M
Porter W
Snowden E
Yee SS
Tong F
Ferguson M
Fleshman EN
Nakagawa H
Falk GW
Ginsberg GG
Kochman ML
Blaesius R
Rustgi AK
Carpenter EL
Source :
Oncotarget [Oncotarget] 2019 Jun 04; Vol. 10 (38), pp. 3592-3604. Date of Electronic Publication: 2019 Jun 04 (Print Publication: 2019).
Publication Year :
2019

Abstract

Barrett's esophagus (BE) is metaplasia of the squamous epithelium to a specialized columnar epithelium. BE progresses through low- and high-grade dysplasia before developing into esophageal adenocarcinoma. The BE microenvironment is not well defined. We compare 12 human clinical BE and adjacent normal squamous epithelium biopsies using single cell immunophenotyping by flow cytometry. A cassette of 19 epithelial and immune cell markers was used to detect differences between cellular compartments in normal and BE tissues. We found that the BE microenvironment has an immunological landscape distinct from adjacent normal epithelium. BE has an increased percentage of epithelial cells with a concomitant decrease in the percentage of immune cells, accompanied by a shift in the immune landscape from a predominantly T cell rich microenvironment in normal tissue to a B cell rich landscape in BE tissue. Hierarchical clustering separates BE and normal samples into two discrete groups based upon our 19-marker panel, but also reveals unexpected, shared phenotypes for three patients. Our results suggest that flow based single cell analysis may have the potential for revealing clinically relevant differences between BE and normal adjacent tissue, and that surface immunophenotypes could identify specific subpopulations from dysplastic tissue for further investigation.<br />Competing Interests: CONFLICTS OF INTEREST E.L.C. receives research support from BD Technologies and Innovations, Janssen, and Merck and travel expenses from AstraZeneca and Foundation Medicine. G.W.F. receives research funding from Interscope. M.L.K. is a consultant to BSC, Dark Canyon Labs, Ferring, and Olympus. F.H., W.P., E.S., M.F., F.T., and R.B. are employees of BD Technologies and Innovation. F.H., W.P., E.S., F.T., and R.B. own stock in BD. M.S., T.A.B., M.D., S.S.Y., E.N.F., H.N., G.G.G., and A.K.R. have no competing interests.

Details

Language :
English
ISSN :
1949-2553
Volume :
10
Issue :
38
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
31217895
Full Text :
https://doi.org/10.18632/oncotarget.26911